Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

Depression Clinical Trial

Official title: Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

Status Active, not recruiting

Clinical Trial Summary

The goal of this fixed order, open-label, dose-escalation study is to investigate the safety and efficacy of specific doses of dimethyltryptamine (DMT) in humans.

Clinical Trial Description

The results of this study will inform the doses to be used in a larger, double-blind, randomized, placebo-controlled, crossover study. Since the goal of the open label study is to inform the double-blind, randomized, placebo-controlled study, the investigators are citing the hypothesis of the latter solely for providing context. The investigators hypothesize that the administration of DMT will result in neuroplastic changes in healthy and depressed subjects. These changes in neuroplasticity will be indexed using electroencephalographic (EEG) measures and tasks. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood. ;

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

• NCT number: NCT04711915
• Study type: Interventional
• Source: Yale University
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: March 17, 2021
• Completion date: December 1, 2024